Human mesenchymal stem cell-conditioned medium improves cardiac function following myocardial infarction

Timmers, Leo; Lim, Sai Kiang; Hoefer, Imo E.; Arslan, Fatih; Lai, Ruenn Chai; Oorschot, Angelique A.M. van; Goumans, Marie–José; Strijder, Chaylendra; Sze, Siu Kwan; Choo, Andre; Piek, Jan J.; Doevendans, Pieter A.; Pasterkamp, Gérard; Kleijn, Dominique P.V. de

doi:10.1016/j.scr.2011.01.001

Cited by 391 publications

(296 citation statements)

References 31 publications

Supporting

Mentioning

277

Contrasting

Unclassified

Order By: Relevance

“…Extensive studies have explored and demonstrated a chemotactic response of MSCs to the site of injury in animal models of cerebral ischemia, TBI and myocardial infarction, and a functional improvement has been observed in clinical studies. [45][46][47][48][49][50][51] Ringden et al 52 showed that MSCs were efficacious in the treatment of hemorrhagic cystitis after allogeneic HSCT, and suggested that MSCs can be used to reverse the toxicities caused by chemoradiotherapy. However, there is little evidence showing that clinical benefits are dependent on the differentiation to tissue or direct repair from infused MSCs.…”

Section: Discussionmentioning

confidence: 99%

Co-transplantation of third-party umbilical cord blood-derived MSCs promotes engraftment in children undergoing unrelated umbilical cord blood transplantation

Lee

Yoo

et al. 2013

Bone Marrow Transplant

View full text Add to dashboard Cite

Success of umbilical cord blood transplantation (UCBT) has been limited by a high rate of graft failure and delayed hematological recovery. It has been postulated that MSCs have hematopoiesis-supportive properties. Therefore, to overcome the limitation of UCBT, third-party UCB-derived MSCs were co-transplanted in recipients receiving unrelated UCBT. Seven patients received UCB and third-party UCB-MSCs. Hematopoietic recovery and transplantation outcomes were compared with historic controls. There was no acute toxicity associated with the infusion of MSCs. The median day to neutrophil engraftment was 19 days in patients, as compared with 24 days in controls (P ¼ 0.03). The median day of platelet engraftment was 47 days and 57 days in patients and controls, respectively (P ¼ 0.26). In addition, there was no engraftment failure in the MSC group. The incidence of acute and chronic GVHD was comparable between the two groups. However, veno-occlusive disease and TRM did not occur in the MSC group. Thirdparty UCB-MSCs infusion was safe and feasible. MSCs may also enhance the engraftment of UCBT and prevent rejection. In addition, MSCs may have a role in decreasing TRM. Randomized, controlled trials are required to confirm these results and longer follow-up will determine the effects of MSCs on the risk of relapse.

show abstract

Section: Discussionmentioning

confidence: 99%

Co-transplantation of third-party umbilical cord blood-derived MSCs promotes engraftment in children undergoing unrelated umbilical cord blood transplantation

Lee

Yoo

et al. 2013

Bone Marrow Transplant

View full text Add to dashboard Cite

show abstract

“…It is now believed that the transplanted cells do not take over the functions of the cells that were lost due to ischemia, but, rather, that they support the recipient's surviving cardiac muscle cells by paracrine signalling, stimulating the angiogenesis in the affected area and reducing the size of myocardial lesion. Indeed, it has been demonstrated that application of medium conditioned by human mesenchymal stem cells (not the cells) also improved the cardiac function in a pig model of myocardial infarction [63].…”

Section: Cardiomyocytes Produced By Differentiation Ofmentioning

confidence: 99%

We heart cultured hearts. A comparative review of methodologies for targeted differentiation and maintenance of cardiomyocytes derived from pluripotent and multipotent stem cells

Arabadjiev¹,

Petkova²,

Chakarov³

et al. 2014

View full text Add to dashboard Cite

Citation: Arabadjiev A, Petkova R, Chakarov S, Pankov R, Zhelev N. We heart cultured hearts. A comparative review of methodologies for targeted differentiation and maintenance of cardiomyocytes derived from pluripotent and multipotent stem cells. AbstractHuman cell lines, including disease cell lines are often superior to routine animal models for the purposes of rapid and safe assessment of the effects of different agents that may modulate myocardial functioning under physiological and pathological conditions. There are several currently existing methodologies for derivation of cardiomyocyte-like cells by targeted differentiation from pluripotent cells and by reprogramming/ transdifferentiation from other types of cells (multipotent progenitors, somatic cells, etc). The present paper reviews the potential sources of cells capable of differentiation along the cardiomyocyte lineage; the existing methodologies for targeted differentiation, outlining the specificities of each method; and the markers for differentiation along the mesodermal and the cardiogenic lineage. The yield of robustly beating cells expressing cardio-specific proteins derived by any of the existing methods, however, still rarely exceeds 70-90 %, even with the newly developed approaches for increasing the differentiation capacity. There still is significant variance in the results obtained by different research groups and even between different experiments carried out in the same laboratory, with the same type of cells and same general type of protocol. Derivation of new lines of human pluripotent and multipotent stem cells according to standardised protocols and in completely defined; xeno-free conditions may increase the reliability and reproducibility of research and speed up the development of potential clinical applications.

show abstract

“…However, it has been suggested that donor cells cannot reside in the heart for a long time after transplantation (9,16,21), and some studies reported a paracrine signaling mechanism by which the donor cells reduced cell apoptosis and fibrosis and increased vasculogenesis to repair the injury (8,35,36).…”

Section: Introductionmentioning

confidence: 99%

Intramuscular Transplantation of Pig Amniotic Fluid-Derived Progenitor Cells Has Therapeutic Potential in a Mouse Model of Myocardial Infarction

et al. 2015

View full text Add to dashboard Cite

Acute myocardial infarction (MI) is a fatal event that causes a large number of deaths worldwide. MI results in pathological remodeling and decreased cardiac function, which could lead to heart failure and fatal arrhythmia. Cell therapy is a potential strategy to repair the damage through enhanced angiogenesis or by modulation of the inflammatory process via paracrine signaling. Amniotic fluid-derived progenitor cells (AFPCs) have been reported to differentiate into several lineages and can be used without ethical concerns or risk of teratoma formation. Since pigs are anatomically, physiologically, and genetically similar to humans, and pregnant pigs can be an abundant source of AFPCs, we used porcine AFPCs (pAFPCs) as our target cells. Intramyocardial injection of AFPCs has been shown to cure MI in animal models. However, intramuscular transplantation of cells has not been extensively investigated. In this study, we investigated the therapeutic potential of intramuscular injection of pAFPCs on acute MI. MI mice were divided into 1) PBS control, 2) medium cell dose (1 × 10 6 cells per leg; cell-M), and 3) high cell dose (4 × 10 6 cells per leg; cell-H) groups. Cells or PBS were directly injected into the hamstring muscle 20 min after MI surgery. Four weeks after MI surgery, the cell-M and cell-H groups exhibited significantly better ejection fraction, significantly greater wall thickness, smaller infarct scar sizes, and lower LV expansion index compared to the PBS group. Using in vivo imaging, we showed that the hamstring muscles from animals in the cell-M and cell-H groups had RFP-positive signals. In summary, intramuscular injection of porcine AFPCs reduced scar size, reduced pathological remodeling, and preserved heart function after MI.

show abstract

Human mesenchymal stem cell-conditioned medium improves cardiac function following myocardial infarction

Cited by 391 publications

References 31 publications

Co-transplantation of third-party umbilical cord blood-derived MSCs promotes engraftment in children undergoing unrelated umbilical cord blood transplantation

Co-transplantation of third-party umbilical cord blood-derived MSCs promotes engraftment in children undergoing unrelated umbilical cord blood transplantation

We heart cultured hearts. A comparative review of methodologies for targeted differentiation and maintenance of cardiomyocytes derived from pluripotent and multipotent stem cells

Intramuscular Transplantation of Pig Amniotic Fluid-Derived Progenitor Cells Has Therapeutic Potential in a Mouse Model of Myocardial Infarction

Contact Info

Product

Resources

About